(AOF) – Nicox, today announced that its Chinese exclusive licensee partner, Ocumension Therapeutics, has submitted a marketing authorization application in China for Zerviate (cetirizine ophthalmic solution), 0.24% for the eye pruritus associated with allergic conjunctivitis. The international ophthalmology company says the approval process is expected to take around 12 months, with a potential commercial launch in China in 2024. Ocumension plans to manufacture the product at its new facility in Suzhou, China.
Zerviate is currently marketed in the United States for the treatment of ocular pruritus associated with allergic conjunctivitis. The prescription allergic conjunctivitis product market in China is expected to reach nearly $500 million by 2030.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.